Lilly’s GLP-1 pill beats older Novo diabetes drug in head-to-head trial
Eli Lilly and Co. and Novo Nordisk have been locked in a fierce battle to control the obesity market, which is projected to reach $100 billion by the end of the decade.
Pharmaceutical
Articles
Eli Lilly to build $5B plant in Virginia—first of 4 U.S. sites to be named this year
Indianapolis-based Lilly said the new plant would create more than 650 jobs in Virginia for engineers, scientists, operations personnel and lab technicians, as well as 1,800 construction jobs.
Health insurance premiums poised to spike over drug costs, tariff threats
In explaining the rising prices, insurers and employers point to two recent factors: the tariffs on pharmaceutical imports and the high cost of new obesity treatments.
Trump’s plan for drug advertising crackdown faces many hurdles
President Donald Trump signed a memo Tuesday that directs the FDA and other agencies to step up enforcement against ubiquitous prescription drug ads on TV, websites and social media.
Lilly rival Novo Nordisk, maker of obesity drug Wegovy, to cut 9,000 jobs
The restructuring, which would eliminate 11% of the company’s workforce, aimed to reduce organizational complexity and speed up decision-making as the company faces a more competitive market for obesity drugs.
Elanco reports pet parasite treatment quickly hit $100M blockbuster status
The sales momentum comes as Elanco prepares to open its $200 million-plus corporate campus next month on the west side of downtown Indianapolis.
World Health Organization adds Mounjaro to its list of essential medicines
The recommendation applies to a range of GLP-1 drugs that also includes Novo Nordisk’s Ozempic and Lilly’s older diabetes treatment, Trulicity.
Trump plans hefty tax on imported drugs, risking higher prices, shortages
The threat comes as Trump also pressures drugmakers to lower prices of pharmaceuticals in the United States.
Mounjaro price hike fuels UK pharmacy battle to retain customers
Eli Lilly and Co. announced this month it would raise the weight-loss treatment’s price by as much as 170%, presenting pharmacies with a dilemma about how much they would pass on to patients.
Lilly’s weight-loss pill moves ahead after pivotal trial
The company’s shares rose as much as 4.3% Tuesday after Eli Lilly announced the trial results for orforglipron.
Lilly signs $1.3B deal with Boston startup for AI-assisted drug development
Superluminal will use its AI-driven platform to discover and optimize small-molecule treatments for G protein-coupled receptors, or GPCRs, which have emerged as a key to conditions such as diabetes and obesity.
Firm tied to Trump Jr. debuts direct sales product for pharma companies
Eli Lilly and Co. has already launched LillyDirect service, which CEO David Ricks says jibes with the administration’s demand for direct sales. Lilly is working with Truepill and Amazon.com Inc.’s pharmacy unit on its platform.
Research on reversing Alzheimer’s reveals lithium as potential key
Seven years of investigation by scientists at Harvard Medical School has revealed that the loss of the metal lithium plays a powerful role in Alzheimer’s disease, a finding that could lead to earlier detection, new treatments and a broader understanding of how the brain ages.
More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects
Seventeen of the complaints also name Eli Lilly and Co. competitor Novo Nordisk Inc. as a defendant and make similar allegations about its GLP-1 drug, Ozempic.
Indiana surpasses more than $1.1B in opioid-related settlements
Attorney General Todd Rokita announced Monday that Indiana is expected to receive another $16.5 million as part of the latest multistate opioid settlement.
Drug manufacturing facility offers new hope in cancer fight
New Jersey-based drugmaker Bristol Myers Squibb this month dedicated its first production facility in Indiana, a former north-side warehouse transformed with $160 million into a clean-room manufacturing site for radiopharmaceutical cancer therapies.
FDA names former pharmaceutical exec to oversee drug program
Dr. George Tidmarsh, a cancer and pediatric specialist, will direct the agency’s Center for Drug Evaluation and Research, which regulates the safety and effectiveness of all U.S. drugs.
Drugmaker telehealth deals risk unnecessary prescribing, Senate probe finds
Partnerships between telehealth companies and pharmaceutical giants Pfizer and Indianapolis-based Eli Lilly and Co. raise concerns about conflicts of interest and inappropriate prescribing, according to a Senate investigation released Thursday.
FDA considers trading faster drug reviews for lower prices
The idea could help the administration achieve one of President Donald Trump’s main health-care goals: ensuring foreign countries aren’t getting a better deal on drugs.
FDA begins sharing rejection letters drugmakers often kept secret
Investors have long asked the FDA to share its reasons for rejecting drugs, arguing that companies can use the agency’s silence on the matter to mislead the market.